Dyno Therapeutics Valuation, Funding & Investors
Dyno Therapeutics is valued at $59M as of May 2020.
Last Dyno Therapeutics valuation
$59M
Seed · May 2020
Last Dyno Therapeutics funding round
$100M
Series A · May 2021
Cumulative funding Dyno Therapeutics raised
$109M
across 2 funding rounds
Key investors in Dyno Therapeutics
CRV
Polaris Partners
Andreessen Horowitz
GV
Lux Capital
Casdin Capital
About Dyno Therapeutics
Dyno Therapeutics is a Harvard spinout that develops an AI-powered CapsidMap platform to design improved adeno-associated virus (AAV) capsids for gene therapy delivery. Rather than developing its own therapy pipeline, the company partners with biopharmaceutical companies to improve vector efficacy, safety, manufacturability, and applicability across diseases affecting tissues such as muscle, eye, the central nervous system, liver, heart, lungs, and kidneys. Its technology builds on intellectual property from George Church's lab at Harvard Medical School.
Founded
2018
HQ
United StatesWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Licensing, Subscription
Valuation
$59M (May 2020)
Dyno Therapeutics Valuation
Dyno Therapeutics is currently valued at $59M, based on its seed round in May 2020.
The $9M round was led by CRV and Polaris Partners.
Dyno Therapeutics valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| May 2020 | Seed | $59M |
Dyno Therapeutics Funding History
Dyno Therapeutics has raised a total of $109M across 2 funding rounds.
Dyno Therapeutics' first fundraising round was a $9M seed round in May 2020. The most recent completed round was a $100M Series A in May 2021.
Dyno Therapeutics funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| May 2021 | Series A | Andreessen Horowitz (lead); GV; Casdin Capital; Polaris Partners; Obvious Ventures; Lux Capital; KdT Ventures; Sahsen Ventures; CRV | $100M | - | Dyno Therapeutics, a Harvard spinout founded by Eric Kelsic and based on George Church's lab IP, develops an AI-powered CapsidMap platform to design improved adeno-associated virus (AAV) capsids for gene therapy delivery to diverse tissues. The company focuses on a technology platform rather than its own therapy pipeline, partnering with biopharma to enhance vector efficacy, safety, manufacturability, and applicability to more diseases like those affecting muscle, eye, CNS, liver, heart, lungs, and kidneys. On May 6, 2021, Dyno raised $100 million in an oversubscribed Series A round led by Andreessen Horowitz, with participation from new investors Casdin Capital, GV, Obvious Ventures, Lux Capital, and founding backers Polaris Partners, CRV, and KdT Ventures. Jorge Conde of Andreessen Horowitz joined the board. The funding supports expansion of CapsidMap, team growth from 50 to 150 employees over two years, and scaling partnerships to meet high demand. Prior to the round, Dyno launched publicly in 2020 with seed funding and deals: Novartis and Sarepta for muscle and eye (up to $2 billion potential), Roche in 2020 for CNS and liver (up to $1.8 billion in milestones). The financing addresses gene therapy's delivery bottleneck using machine learning and high-throughput in vivo data, positioning Dyno as infrastructure for the field amid a wave of large gene therapy financings. |
| May 2020 | Seed | CRV (lead); Polaris Partners (lead) | $9M | $59M | Dyno Therapeutics, a biotech company applying AI and quantitative in vivo experiments to design improved AAV capsids for gene therapies, launched in 2018. The company emerged from stealth in May 2020 with partnerships from Novartis and Sarepta Therapeutics, potentially worth over $2 billion in upfront payments, research support, milestones, and royalties. On approximately November 5, 2020, Dyno Therapeutics completed a Series Seed-N funding round led by CRV and Polaris Partners, raising $2 million at a post-money valuation of $59.17 million. This followed their initial $9 million financing in late 2018, also co-led by the same investors. The technology stems from Harvard Medical School's George Church lab, with exclusive licensing options. By May 2021, Dyno raised a $100 million Series A led by Andreessen Horowitz, with participation from Casdin Capital, Google Ventures, Lux Capital, Obvious Ventures, and returning investors including CRV and Polaris Partners, at a post-money valuation of $539.27 million. The funds supported platform expansion to new tissues like lung, heart, and kidney, team growth from 50 to triple that size, and additional partnerships. |
Who has invested in Dyno Therapeutics?
9 investors have backed Dyno Therapeutics across its funding rounds, including CRV, Polaris Partners, Andreessen Horowitz, GV, Lux Capital and Casdin Capital.
Lead investors include Andreessen Horowitz, CRV and Polaris Partners.
Dyno Therapeutics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| Boston, MA | 2 | Lead | May 2020 | |
| United States | 2 | Lead | May 2020 | |
| San Francisco, CA | 1 | Participant | May 2021 | |
| New York City, NY | 1 | Participant | May 2021 | |
| San Francisco, CA | 1 | Participant | May 2021 | |
| New York City, NY | 1 | Participant | May 2021 | |
| Austin, TX | 1 | Participant | May 2021 | |
This data is available for Pro users. Sign up to see all 9 Dyno Therapeutics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialDyno Therapeutics Competitors
Dyno Therapeutics competitors include listed companies like Brand Engagement Network and Airship AI, and private ones like Genevation, LungLife AI, MDBox and Digital Diagnostics.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
 Stevenage | Private | - | - | $64M | - | |
| Los Angeles, CA | Private | - | - | $60M | - | |
| Austin, TX | Private | - | - | $65M | - | |
 Mainz | Private | - | - | $68M | - | |
| United States | Publicly listed | $275K | ($4M) | $53M | - | |
| United States | Publicly listed | $15M | ($5M) | $67M | 3.6x |
Dyno Therapeutics Public Comps
Dyno Therapeutics is still privately-owned, but its public comps include Clene, Xilio Therapeutics, Dogwood Therapeutics, Labiana Health, Sangamo Therapeutics, Lixte Biotechnology, MiNK Therapeutics, K Pharma, Heron Therapeutics and Avecho Biotechnology.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $200K | ($22M) | 358.3x | 281.5x | (3.2x) | (3.5x) | |||
| $44M | ($33M) | - | - | - | - | |||
| - | ($34M) | - | - | (1.4x) | - | |||
| $87M | $13M | 1.1x | 1.1x | 7.5x | 7.4x | |||
| $40M | ($117M) | 1.3x | 1.3x | (0.4x) | - | |||
| - | ($6M) | - | - | (8.0x) | - | |||
| - | ($12M) | - | 21.0x | (4.1x) | - | |||
| - | ($6M) | - | - | (8.7x) | - | |||
This data is available for Pro users. Sign up to see all Dyno Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Dyno Therapeutics
| When was Dyno Therapeutics founded? | Dyno Therapeutics was founded in 2018. |
| Where is Dyno Therapeutics headquartered? | Dyno Therapeutics is headquartered in United States. |
| Is Dyno Therapeutics publicly listed? | No, Dyno Therapeutics is a private, VC-backed company. |
| What is Dyno Therapeutics' valuation? | Dyno Therapeutics was last valued at $59M in its seed round in May 2020. |
| How much funding has Dyno Therapeutics raised? | Dyno Therapeutics has raised $109M across 2 funding rounds. |
| What was Dyno Therapeutics' last funding round? | Dyno Therapeutics' last funding round was a $100M Series A in May 2021, led by Andreessen Horowitz. |
| Who are Dyno Therapeutics' investors? | Dyno Therapeutics' investors include Polaris Partners, CRV, GV, Casdin Capital, Obvious Ventures, Lux Capital, KdT Ventures, Andreessen Horowitz and Sahsen Ventures. |
| Which companies are comparable to Dyno Therapeutics? | Companies comparable to Dyno Therapeutics include Genevation, LungLife AI, MDBox, Digital Diagnostics, Brand Engagement Network and Airship AI. |
See companies similar to Dyno Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.